|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FZD5 |
Gene summary for FZD5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FZD5 | Gene ID | 7855 |
| Gene name | frizzled class receptor 5 | |
| Gene Alias | C2orf31 | |
| Cytomap | 2q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q13467 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7855 | FZD5 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.23e-04 | 4.73e-01 | -0.1088 |
| 7855 | FZD5 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.89e-28 | 7.91e-01 | -0.1954 |
| 7855 | FZD5 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.67e-02 | 6.33e-01 | -0.2602 |
| 7855 | FZD5 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.06e-02 | 4.42e-01 | -0.2061 |
| 7855 | FZD5 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.48e-04 | 5.00e-01 | -0.0179 |
| 7855 | FZD5 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.24e-02 | 4.52e-01 | 0.0131 |
| 7855 | FZD5 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.70e-03 | 2.71e-01 | 0.294 |
| 7855 | FZD5 | A015-C-203 | Human | Colorectum | FAP | 3.46e-02 | -1.18e-01 | -0.1294 |
| 7855 | FZD5 | A001-C-119 | Human | Colorectum | FAP | 2.01e-02 | -1.94e-01 | -0.1557 |
| 7855 | FZD5 | A001-C-108 | Human | Colorectum | FAP | 2.75e-02 | -1.63e-01 | -0.0272 |
| 7855 | FZD5 | A002-C-205 | Human | Colorectum | FAP | 4.71e-02 | -1.52e-01 | -0.1236 |
| 7855 | FZD5 | A001-C-104 | Human | Colorectum | FAP | 2.42e-02 | -1.55e-01 | 0.0184 |
| 7855 | FZD5 | A015-C-006 | Human | Colorectum | FAP | 5.93e-03 | -1.94e-01 | -0.0994 |
| 7855 | FZD5 | A002-C-114 | Human | Colorectum | FAP | 4.22e-02 | -1.79e-01 | -0.1561 |
| 7855 | FZD5 | A015-C-104 | Human | Colorectum | FAP | 2.05e-06 | -1.94e-01 | -0.1899 |
| 7855 | FZD5 | A002-C-116 | Human | Colorectum | FAP | 1.24e-03 | -1.38e-01 | -0.0452 |
| 7855 | FZD5 | HCC1_Meng | Human | Liver | HCC | 6.08e-64 | 1.06e-01 | 0.0246 |
| 7855 | FZD5 | HCC2_Meng | Human | Liver | HCC | 6.65e-25 | 1.78e-01 | 0.0107 |
| 7855 | FZD5 | HCC1 | Human | Liver | HCC | 1.03e-03 | 1.99e+00 | 0.5336 |
| 7855 | FZD5 | HCC2 | Human | Liver | HCC | 8.35e-07 | 1.81e+00 | 0.5341 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009031621 | Liver | HCC | positive regulation of intracellular protein transport | 121/7958 | 160/18723 | 1.27e-17 | 1.39e-15 | 121 |
| GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
| GO:000662612 | Liver | HCC | protein targeting to mitochondrion | 82/7958 | 100/18723 | 4.93e-16 | 4.05e-14 | 82 |
| GO:190300811 | Liver | HCC | organelle disassembly | 89/7958 | 114/18723 | 8.68e-15 | 5.73e-13 | 89 |
| GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
| GO:000042211 | Liver | HCC | autophagy of mitochondrion | 64/7958 | 81/18723 | 1.96e-11 | 7.72e-10 | 64 |
| GO:006172611 | Liver | HCC | mitochondrion disassembly | 64/7958 | 81/18723 | 1.96e-11 | 7.72e-10 | 64 |
| GO:190374911 | Liver | HCC | positive regulation of establishment of protein localization to mitochondrion | 33/7958 | 36/18723 | 7.67e-10 | 2.37e-08 | 33 |
| GO:19039551 | Liver | HCC | positive regulation of protein targeting to mitochondrion | 30/7958 | 32/18723 | 1.19e-09 | 3.58e-08 | 30 |
| GO:001082112 | Liver | HCC | regulation of mitochondrion organization | 96/7958 | 144/18723 | 3.82e-09 | 1.02e-07 | 96 |
| GO:190353311 | Liver | HCC | regulation of protein targeting | 60/7958 | 81/18723 | 7.70e-09 | 1.94e-07 | 60 |
| GO:190374711 | Liver | HCC | regulation of establishment of protein localization to mitochondrion | 41/7958 | 50/18723 | 1.14e-08 | 2.83e-07 | 41 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
| GO:190321411 | Liver | HCC | regulation of protein targeting to mitochondrion | 36/7958 | 44/18723 | 1.02e-07 | 1.98e-06 | 36 |
| GO:000170111 | Liver | HCC | in utero embryonic development | 204/7958 | 367/18723 | 2.44e-07 | 4.30e-06 | 204 |
| GO:190314611 | Liver | HCC | regulation of autophagy of mitochondrion | 28/7958 | 33/18723 | 6.57e-07 | 1.03e-05 | 28 |
| GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
| GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
| GO:000189211 | Liver | HCC | embryonic placenta development | 50/7958 | 82/18723 | 5.62e-04 | 3.61e-03 | 50 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
| hsa04310 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
| hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
| hsa043101 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
| hsa050102 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
| hsa050222 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
| hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa050103 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
| hsa050223 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
| hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa050104 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
| hsa050224 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
| hsa052252 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
| hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | AD |
| WNT4 | FZD5_LRP5 | WNT4_FZD5_LRP5 | WNT | CRC | AD |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | ADJ |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | MSI-H |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | SER |
| WNT5A | FZD5 | WNT5A_FZD5 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | Esophagus | ESCC |
| WNT10A | FZD5_LRP6 | WNT10A_FZD5_LRP6 | WNT | Esophagus | ESCC |
| WNT10B | FZD5_LRP6 | WNT10B_FZD5_LRP6 | WNT | Esophagus | ESCC |
| WNT2 | FZD5_LRP6 | WNT2_FZD5_LRP6 | WNT | Esophagus | ESCC |
| WNT2B | FZD5_LRP6 | WNT2B_FZD5_LRP6 | WNT | Esophagus | ESCC |
| WNT3A | FZD5_LRP6 | WNT3A_FZD5_LRP6 | WNT | Esophagus | ESCC |
| WNT7B | FZD5_LRP6 | WNT7B_FZD5_LRP6 | WNT | Esophagus | ESCC |
| WNT9A | FZD5_LRP6 | WNT9A_FZD5_LRP6 | WNT | Esophagus | ESCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FZD5 | SNV | Missense_Mutation | rs772754333 | c.533C>T | p.Ser178Leu | p.S178L | Q13467 | protein_coding | tolerated(0.36) | benign(0.038) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| FZD5 | SNV | Missense_Mutation | novel | c.741C>A | p.Phe247Leu | p.F247L | Q13467 | protein_coding | tolerated(0.97) | benign(0.348) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FZD5 | SNV | Missense_Mutation | rs753318203 | c.577N>T | p.Arg193Cys | p.R193C | Q13467 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| FZD5 | SNV | Missense_Mutation | novel | c.103G>A | p.Glu35Lys | p.E35K | Q13467 | protein_coding | tolerated(0.05) | possibly_damaging(0.785) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FZD5 | SNV | Missense_Mutation | c.1627C>T | p.Arg543Cys | p.R543C | Q13467 | protein_coding | deleterious(0.02) | benign(0.248) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FZD5 | SNV | Missense_Mutation | c.263N>T | p.Ser88Phe | p.S88F | Q13467 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FZD5 | insertion | Frame_Shift_Ins | novel | c.1501_1502insT | p.Trp501LeufsTer98 | p.W501Lfs*98 | Q13467 | protein_coding | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | ||
| FZD5 | SNV | Missense_Mutation | novel | c.1153C>A | p.Pro385Thr | p.P385T | Q13467 | protein_coding | tolerated(0.28) | possibly_damaging(0.904) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FZD5 | SNV | Missense_Mutation | novel | c.242A>G | p.Asp81Gly | p.D81G | Q13467 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
| FZD5 | insertion | Frame_Shift_Ins | novel | c.1046_1047insG | p.Asn350GlnfsTer249 | p.N350Qfs*249 | Q13467 | protein_coding | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7855 | FZD5 | G PROTEIN COUPLED RECEPTOR, KINASE, CELL SURFACE | antibody | 381118907 | VANTICTUMAB | |
| 7855 | FZD5 | G PROTEIN COUPLED RECEPTOR, KINASE, CELL SURFACE | antagonist | CHEMBL2364652 | VANTICTUMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |